It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Variations in N-acylethanolamines (NAE) levels are associated with obesity and metabolic comorbidities. Their role in the gut remains unclear. Therefore, we generated a mouse model of inducible intestinal epithelial cell (IEC)-specific deletion of N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD), a key enzyme involved in NAE biosynthesis (Napepld∆IEC). We discovered that Napepld∆IEC mice are hyperphagic upon first high-fat diet (HFD) exposure, and develop exacerbated obesity and steatosis. These mice display hypothalamic Pomc neurons dysfunctions and alterations in intestinal and plasma NAE and 2-acylglycerols. After long-term HFD, Napepld∆IEC mice present reduced energy expenditure. The increased steatosis is associated with higher gut and liver lipid absorption. Napepld∆IEC mice display altered gut microbiota. Akkermansia muciniphila administration partly counteracts the IEC NAPE-PLD deletion effects. In conclusion, intestinal NAPE-PLD is a key sensor in nutritional adaptation to fat intake, gut-to-brain axis and energy homeostasis and thereby constitutes a novel target to tackle obesity and related disorders.
Obesity is associated with altered N-acylethanolamine levels (NAE). Here the authors show that deletion of the gene encoding N-acylphosphatidylethanolamine phospholipase D, a key enzyme for NAE synthesis, in intestinal cells of mice leads to the development of obesity and hepatic steatosis via a mechanism involving the gut-brain axis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Université catholique de Louvain, Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Walloon Excellence in Life sciences and BIOtechnology (WELBIO), UCLouvain, Bruxelles, Belgium (GRID:grid.7942.8) (ISNI:0000 0001 2294 713X)
2 Institut Curie, CNRS, Paris, France (GRID:grid.418596.7) (ISNI:0000 0004 0639 6384)
3 UCLouvain, Université catholique de Louvain, Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, Bruxelles, Belgium (GRID:grid.7942.8) (ISNI:0000 0001 2294 713X)
4 Wageningen University, Laboratory of Microbiology, Wageningen, the Netherlands (GRID:grid.4818.5) (ISNI:0000 0001 0791 5666)
5 Sorbonne Paris Cité, BFA, UMR8251, CNRS, Université Paris Diderot, Paris, France (GRID:grid.4444.0) (ISNI:0000 0001 2112 9282)
6 Université Laval, Quebec Heart and Lung Institute Research Centre, G1V 0A6 Quebec City, Canada (GRID:grid.23856.3a) (ISNI:0000 0004 1936 8390)
7 Université Laval, Quebec Heart and Lung Institute Research Centre, G1V 0A6 Quebec City, Canada (GRID:grid.23856.3a) (ISNI:0000 0004 1936 8390); Université Laval, Institute of Nutrition and Functional Foods, G1V 0A6 Quebec City, Canada (GRID:grid.23856.3a) (ISNI:0000 0004 1936 8390); Consiglio Nazionale delle Ricerche, Endocannabinoid Research Group, Institute of Biomolecular Chemistry, 80078 Pozzuoli, Napoli, Italy (GRID:grid.5326.2) (ISNI:0000 0001 1940 4177)